Case report: Approaches to treatment-refractory and super-refractory glutamic acid decarboxylase antibody-spectrum disorders

Front Immunol. 2024 Jan 8:14:1297340. doi: 10.3389/fimmu.2023.1297340. eCollection 2023.

Abstract

Background: Glutamic acid decarboxylase antibody-spectrum disorders (GAD-SDs) include a group of autoimmune neurological diseases associated with neuronal excitability, most noticeably stiff person syndrome. Immune modulators are the mainstay of treatment, but a significant number of patients remain refractory.

Methods: We present our single-center experience of eight cases of GAD-SD, two of which were refractory to immune modulatory treatments.

Results: Of the two cases that were refractory to immunomodulation, one showed significant improvement with bilateral globus pallidus interna deep brain stimulation (GPi DBS) placement, and the other showed significant improvement with autologous hematopoietic stem cell transplant (aHSCT).

Discussion: To our knowledge, this is the first instance of GPi DBS placement being noted to improve GAD-SD movements.

Keywords: GAD-65; deep brain stimulation; rituximab; stem cells; stiff person syndrome.

Publication types

  • Case Reports

MeSH terms

  • Antibodies
  • Autoimmune Diseases of the Nervous System*
  • Glutamate Decarboxylase*
  • Humans
  • Immunomodulation

Substances

  • Glutamate Decarboxylase
  • Antibodies

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.